Exelixis, Inc. (EXEL) Receives $30.00 Average PT from Brokerages

Shares of Exelixis, Inc. (NASDAQ:EXEL) have received a consensus rating of “Hold” from the thirteen analysts that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $30.00.

A number of analysts recently weighed in on the stock. BidaskClub lowered shares of Exelixis from a “hold” rating to a “sell” rating in a report on Thursday, April 25th. Morgan Stanley set a $27.00 target price on shares of Exelixis and gave the stock a “hold” rating in a report on Thursday, May 2nd. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $26.00 target price on the stock in a report on Tuesday, April 16th. Oppenheimer decreased their target price on shares of Exelixis from $40.00 to $31.00 and set an “outperform” rating on the stock in a report on Wednesday, February 13th. Finally, ValuEngine lowered shares of Exelixis from a “hold” rating to a “sell” rating in a report on Thursday, April 25th.

Exelixis stock traded up $0.57 during midday trading on Monday, reaching $19.70. 605,319 shares of the stock were exchanged, compared to its average volume of 3,721,221. The company has a current ratio of 7.56, a quick ratio of 7.48 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $5.77 billion, a PE ratio of 13.78, a price-to-earnings-growth ratio of 0.38 and a beta of 2.06. Exelixis has a 52 week low of $13.42 and a 52 week high of $25.31.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.24 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.24. The business had revenue of $215.49 million for the quarter, compared to analyst estimates of $206.06 million. Exelixis had a net margin of 75.97% and a return on equity of 37.21%. Exelixis’s revenue was up .8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.40 EPS. Research analysts forecast that Exelixis will post 1.09 earnings per share for the current year.

In other news, Director George A. Scangos sold 5,000 shares of the company’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $25.03, for a total value of $125,150.00. Following the completion of the sale, the director now owns 1,278,031 shares of the company’s stock, valued at approximately $31,989,115.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lance Willsey sold 50,000 shares of the company’s stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $20.36, for a total transaction of $1,018,000.00. Following the completion of the sale, the director now directly owns 368,273 shares of the company’s stock, valued at approximately $7,498,038.28. The disclosure for this sale can be found here. In the last three months, insiders sold 941,862 shares of company stock valued at $21,143,292. Corporate insiders own 4.50% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Icon Wealth Partners LLC purchased a new stake in Exelixis during the 1st quarter valued at $27,000. Kore Private Wealth LLC purchased a new stake in Exelixis during the 1st quarter valued at $36,000. JOYN Advisors Inc. boosted its position in Exelixis by 334.2% during the 4th quarter. JOYN Advisors Inc. now owns 1,524 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 1,173 shares during the period. FTB Advisors Inc. boosted its position in Exelixis by 312.0% during the 4th quarter. FTB Advisors Inc. now owns 1,545 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,170 shares during the period. Finally, Rockefeller Capital Management L.P. purchased a new stake in Exelixis during the 1st quarter valued at $40,000. 76.73% of the stock is owned by institutional investors and hedge funds.

Exelixis Company Profile

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Recommended Story: Bear Market – How and Why They Occur

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.